Clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in postpartum women with breast cancer

被引:0
|
作者
Dou, He [1 ]
Jia, Siyuan [1 ]
Ba, Yuling [1 ]
Luo, Danli [1 ]
Yu, Pingyang [1 ]
Li, Fucheng [1 ]
Wang, Youyu [1 ]
Chen, Xingyan [1 ]
Xiao, Min [1 ]
机构
[1] Harbin Med Univ, Dept Breast Surg, Canc Hosp, 150 Haping Rd, Harbin 150081, Heilongjiang, Peoples R China
关键词
Breast cancer; Neoadjuvant chemotherapy; Pathologic complete response; Pregnancy; Postpartum breast cancer; MAMMARY-GLAND INVOLUTION; YOUNG-WOMEN; PREGNANCY; PROGNOSIS; DIAGNOSIS; SURVIVAL; COLLAGEN; EPIDEMIOLOGY; MACROPHAGES; MECHANISMS;
D O I
10.1007/s00432-023-05194-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeBreast cancer (BC) is currently the leading cause of death in women worldwide. Studies have confirmed that pregnancy is an independent factor affecting the survival of BC patients. BC found during pregnancy, lactation, or shortly after delivery is what we used to think of as pregnancy-associated breast cancer (PABC). The current expert definition of this concept is not uniform; however, there is growing evidence that postpartum breast cancer (PPBC) differs from other types of BC in terms of both biological features and prognosis, with a slightly different focus on diagnosis and treatment. With the increase of female reproductive age population and changes in fertility policies in China, patients with PPBC are receiving increasing attention. Here, we systematically analyzed the clinicopathological characteristics and chemotherapeutic response of patients with PPBC. We retrospectively analyzed the clinicopathological data, molecular subtypes, chemotherapy regimens, and pathological complete remission (pCR) rates of 1343 patients with non-metastatic BC at Harbin Medical University Cancer Hospital from January 1, 2012 to May 31, 2023. The categorical data were compared by chi-square test and Fisher exact test using logistic regression model. Predictor variables with P < 0.05 in the univariate analysis were included in the multivariate regression analysis to investigate the relationship between different age groups and pCR.ResultsA total of 714 patients were eligible for analysis in this study, and 667 patients had a history of pregnancy, 40 (5.6%) of whom were PPBC patients. When diagnosed with BC, patients with PPBC were younger, more likely to undergo breast-conserving surgery (BCS), and more likely to achieve pCR (P < 0.05). In molecular typing, human epidermal growth factor receptor 2 (HER-2)-positive and triple-negative breast cancer (TNBC) were more frequent. In the entire cohort, HER-2 expression and delivery status were independent predictors of pCR rates in BC patients after neoadjuvant chemotherapy (NAC).ConclusionOur findings suggest that postpartum status is an independent predictor of pCR attainment in BC patients. PPBC is more sensitive to chemotherapy than other patients.We need to pay more attention to this group and achieve individualized treatment, which will help us treat BC better and provide new targets and blueprints for our clinical therapy.
引用
收藏
页码:14185 / 14204
页数:20
相关论文
共 50 条
  • [1] Clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in postpartum women with breast cancer
    He Dou
    Siyuan Jia
    Yuling Ba
    Danli Luo
    Pingyang Yu
    Fucheng Li
    Youyu Wang
    Xingyan Chen
    Min Xiao
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 14185 - 14204
  • [2] Pathologic Complete Response Rate and Clinical Outcome of Metaplastic Breast Carcinoma After Neoadjuvant Chemotherapy
    Han, Min
    Zhang, Huina
    Clark, Beth
    Dabbs, David
    Bhargava, Rohit
    [J]. LABORATORY INVESTIGATION, 2018, 98 : 67 - 68
  • [3] Pathologic Complete Response Rate and Clinical Outcome of Metaplastic Breast Carcinoma After Neoadjuvant Chemotherapy
    Han, Min
    Zhang, Huina
    Clark, Beth
    Dabbs, David
    Bhargava, Rohit
    [J]. MODERN PATHOLOGY, 2018, 31 : 67 - 68
  • [4] Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
    Zhu, Jiujun
    Li, Jianbin
    Fan, Zhimin
    Wang, Haibo
    Zhang, Jianguo
    Yin, Yongmei
    Fu, Peifen
    Geng, Cuizhi
    Jin, Feng
    Jiang, Zefei
    Liu, Zhenzhen
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (16)
  • [5] Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
    Carolin Müller
    Gilda Schmidt
    Ingolf Juhasz-Böss
    Lisa Jung
    Sarah Huwer
    Erich-Franz Solomayer
    Stephanie Juhasz-Böss
    [J]. Archives of Gynecology and Obstetrics, 2021, 304 : 1065 - 1071
  • [6] Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
    Mueller, Carolin
    Schmidt, Gilda
    Juhasz-Boess, Ingolf
    Jung, Lisa
    Huwer, Sarah
    Solomayer, Erich-Franz
    Juhasz-Boess, Stephanie
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 304 (04) : 1065 - 1071
  • [7] Demographic Determinants of Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer
    Anderson, Lisa
    Daniele, Karla
    Hayes, Madison
    Dancel, Canice Lei
    Dhanasekara, Samudani
    Rahman, Rakhshanda
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 2) : S383 - S384
  • [8] Pathologic complete response after neoadjuvant chemotherapy in breast cancer molecular subtypes
    Sari, E.
    Aksoy, S.
    Dogan, M.
    Altinbas, M.
    Zengin, N.
    Ozisik, Y.
    Altundag, K.
    [J]. BREAST, 2015, 24 : S99 - S99
  • [9] Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy
    Hee Jun Choi
    Jai Min Ryu
    Isaac Kim
    Seok Jin Nam
    Seok Won Kim
    Jonghan Yu
    Jeong Eon Lee
    Se Kyung Lee
    [J]. Breast Cancer Research and Treatment, 2019, 176 : 591 - 596
  • [10] Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy
    Choi, Hee Jun
    Ryu, Jai Min
    Kim, Isaac
    Nam, Seok Jin
    Kim, Seok Won
    Yu, Jonghan
    Lee, Jeong Eon
    Lee, Se Kyung
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) : 591 - 596